Market Research Report
US Market Report for Orthopedic Bone Graft Substitutes 2017 - MedCore
|Published by||iData Research Inc.||Product code||454932|
|Published||Content info||589 Pages
Delivery time: 1-2 business days
|US Market Report for Orthopedic Bone Graft Substitutes 2017 - MedCore|
|Published: March 1, 2017||Content info: 589 Pages||
Bone is a biologically active tissue and will regenerate whenever possible; however, there are instances where the damage is significant enough to warrant a scaffold to help rejoin the fissure or cavity. Bone grafting is a surgical procedure in which damaged bone is replaced with autograft tissue, allograft tissue or a bone graft substitute, which can be either synthetic or metal.
During an autograft procedure, tissue is harvested from the patient's iliac crest, or possibly the distal femur or proximal tibia, and placed at the injury site. An allograft procedure uses donated cadaveric tissue. A grafting procedure using a bone graft substitute replaces human tissue with a synthetic or metal material. For the purposes of this report, metal replacement materials will be excluded, as they are not considered biomaterials.
As of 2016, the synthetic bone grafts accounted for the largest portion of the market followed by the demineralized bone matrix (DBM) grafts. Market growth has been supported by the strong adoption of the BMP growth factor market, which is represented by Medtronic's INFUSE® product. Furthermore, the fast growing cellular allograft market has benefited the bone graft substitute market by allowing greater osteogenic properties with the use of stem cells. The recent resurgence of growth in the cheaper allograft material market has pushed DBM prices lower in order to stay competitive.
The synthetic bone graft segment surpassed the DBM segment due to both a higher ASP and stronger unit sales growth in the U.S. market. Synthetic grafts are more commonly used in spinal surgeries rather than applications involving larger volumes, as with fracture repair. These large volume indications are the reason that cheaper options, such as allograft bone, play an important role in the market.